Rhumbline Advisers Cullinan Oncology, Inc. Transaction History

Rhumbline Advisers

$113 Billion
Q2 2025

A detailed history of Rhumbline Advisers transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 74,105 shares of CGEM stock, worth $477,977. This represents 0.0% of its overall portfolio holdings.

Number of Shares

74,105

Previous 71,338 3.88%

Holding current value

$477,977

Previous $540,000 3.33%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$7.13 - $9.08 $19,728 - $25,124	2,767 Added 3.88%	74,105 $558,000
Q1 2025 Apr 08, 2025	BUY	$7.57 - $12.68 $23,694 - $39,688	3,130 Added 4.59%	71,338 $572,000
Q4 2024 May 29, 2025	SELL	$10.77 - $17.6 $33,710 - $55,088	-3,130 Reduced 4.39%	68,208 $830,000
Q4 2024 Jan 30, 2025	BUY	$10.77 - $17.6 $57,597 - $94,124	5,348 Added 8.51%	68,208 $830,000
Q3 2024 Nov 12, 2024	BUY	$16.03 - $20.86 $136,399 - $177,497	8,509 Added 15.66%	62,860 $1.05 Million
Q2 2024 Aug 01, 2024	BUY	$15.63 - $29.35 $119,553 - $224,498	7,649 Added 16.38%	54,351 $947,000
Q1 2024 May 09, 2024	BUY	$10.17 - $19.02 $9,885 - $18,487	972 Added 2.13%	46,702 $795,000
Q4 2023 Feb 08, 2024	BUY	$7.89 - $10.23 $3,873 - $5,022	491 Added 1.09%	45,730 $465,000
Q3 2023 Nov 09, 2023	SELL	$9.05 - $11.72 $8,941 - $11,579	-988 Reduced 2.14%	45,239 $409,000
Q2 2023 Aug 08, 2023	SELL	$8.8 - $13.4 $42,820 - $65,204	-4,866 Reduced 9.52%	46,227 $497,000
Q1 2023 May 11, 2023	BUY	$10.2 - $11.91 $44,880 - $52,404	4,400 Added 9.42%	51,093 $523,000
Q4 2022 Feb 14, 2023	BUY	$9.72 - $13.62 $8,854 - $12,407	911 Added 1.99%	46,693 $493,000
Q3 2022 Nov 10, 2022	BUY	$11.82 - $15.42 $31,429 - $41,001	2,659 Added 6.17%	45,782 $587,000
Q2 2022 Aug 11, 2022	BUY	$7.31 - $13.55 $80,980 - $150,106	11,078 Added 34.57%	43,123 $553,000
Q1 2022 May 12, 2022	BUY	$10.47 - $16.75 $15,129 - $24,203	1,445 Added 4.72%	32,045 $336,000
Q4 2021 Feb 10, 2022	SELL	$15.36 - $25.0 $6,528 - $10,625	-425 Reduced 1.37%	30,600 $472,000
Q3 2021 Nov 12, 2021	BUY	$22.56 - $29.68 $360,914 - $474,820	15,998 Added 106.46%	31,025 $700,000
Q2 2021 Aug 05, 2021	BUY	$24.96 - $41.25 $85,937 - $142,023	3,443 Added 29.72%	15,027 $387,000
Q1 2021 May 06, 2021	BUY	$28.0 - $53.42 $324,352 - $618,817	11,584 New	11,584 $483,000

Others Institutions Holding CGEM

# of Institutions

152

Shares Held

66.6M

Call Options Held

10.6K

Put Options Held

917K

View Full List

About Cullinan Oncology, Inc.

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $294M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

More about CGEM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Cullinan Oncology, Inc. Transaction History